Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001618835-23-000001
Filing Date
2023-01-06
Accepted
2023-01-06 16:53:12
Documents
65
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q evfm-20220930.htm   iXBRL 10-Q 2824119
2 EX-31.1 evfm-9302022xex311.htm EX-31.1 19870
3 EX-32.1 evfm-9302022xex321.htm EX-32.1 10954
4 EX-32.2 evfm-9302022xex312.htm EX-32.2 19732
  Complete submission text file 0001618835-23-000001.txt   11546420

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT evfm-20220930.xsd EX-101.SCH 63670
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT evfm-20220930_cal.xml EX-101.CAL 76357
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT evfm-20220930_def.xml EX-101.DEF 432573
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT evfm-20220930_lab.xml EX-101.LAB 758877
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT evfm-20220930_pre.xml EX-101.PRE 531800
59 EXTRACTED XBRL INSTANCE DOCUMENT evfm-20220930_htm.xml XML 1995907
Mailing Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130
Business Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130 (858) 550-1900
Evofem Biosciences, Inc. (Filer) CIK: 0001618835 (see all company filings)

EIN.: 208527075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36754 | Film No.: 23515666
SIC: 2834 Pharmaceutical Preparations